{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T16:23:29Z","timestamp":1757780609818},"reference-count":21,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDS"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Drugs are related with various adverse drug reactions (ADRs), however,\nmany unexpected ADRs of drugs are reported through post-marketing surveillance.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Aim:<\/jats:title>\n<jats:p>The current study's goal is to uncover potential signals connected with FDA-approved medications\nin the United States (2013).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Open Vigil 2.1-MedDRA-v24 (data 20004Q1-2021Q3) was used as a tool to query the\nFAERS data. To find possible signals, disproportionality measures such as Proportional Reporting\nRatio (PRR 2) with associated Chi-square value, Reporting Odds Ratio (ROR 2) with 95%\nconfidence interval, and case count (3) were calculated<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>A total of eight potential signals were identified with five drugs. Positive signals were\nfound with pomalidomide, canagliflozin, dolutegravir sodium, macitentan and ibrutinib.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>However, further causality assessment is required to confirm the association of these\ndrugs with identified potential signals.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0115748863276447231108092936","type":"journal-article","created":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T10:16:02Z","timestamp":1700648162000},"page":"395-401","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Identification of Novel Signals Associated with US-FDA Approved Drugs\n(2013) Using Disproportionality Analysis"],"prefix":"10.2174","volume":"19","author":[{"given":"Sourabh","family":"Raghuvanshi","sequence":"first","affiliation":[{"name":"Department of Clinical Research, Delhi Pharmaceutical Science and Research University (DPSRU), New Delhi,\n110017, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Akhlaquer","family":"Rahman","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics and Industrial Pharmacy, College of Pharmacy, Taif University,\nTaif, 21944, Kingdom of Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahesh Kumar","family":"Posa","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Technology Management, SVKM\u2019S NMIMS, Polepally SEZ,\nJadcherla, Hyderabad, 509301, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anoop","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Delhi Pharmaceutical Sciences and Research\nUniversity (DPSRU), New Delhi, 110017, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"429","DOI":"10.2165\/00002018-199921060-00001","volume":"21","author":"Meyboom R.H.B.","year":"1999","unstructured":"Meyboom R.H.B.; Egberts A.C.; Gribnau F.W.J.; Hekster Y.A.; Pharmacovigilance in perspective. Drug Saf  1999,21(6),429-447","journal-title":"Drug Saf"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s00228-008-0475-9","volume":"64","author":"H\u00e4rmark L.","year":"2008","unstructured":"H\u00e4rmark L.; van Grootheest A.C.; Pharmacovigilance: Methods, recent developments and future perspectives. Eur J Clin Pharmacol  2008,64(8),743-752","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=3","unstructured":"Practical aspects of signal detection in pharmacovigilance.  Available from:\n https:\/\/cioms.ch\/wp-content\/uploads\/2018\/03\/WG8-Signal-Detection.pdf(Accessed on 02-07-2022)."},{"key":"ref=4","unstructured":"Center for Drug Evaluation and Research. FDA Adverse Event Reporting System (FAERS) Public Dashboard. U.S. Food and Drug Administration.   Available from:  https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-public-dashboard(Accessed on 02-07-2022)."},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"e0157753","DOI":"10.1371\/journal.pone.0157753","volume":"11","author":"B\u00f6hm R.","year":"2016","unstructured":"B\u00f6hm R.; von Hehn L.; Herdegen T.; OpenVigil FDA \u2013 Inspection of U.S. American adverse drug events pharmacovigilance data and novel clinical applications. PLoS One  2016,11(6),e0157753","journal-title":"PLoS One"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"964","DOI":"10.3389\/fphar.2020.00964","volume":"11","author":"Vieira J.M.L.","year":"2020","unstructured":"Vieira J.M.L.; de Matos G.C.; da Silva F.A.B.; Bracken L.E.; Peak M.; Lima E.C.; Serious adverse drug reactions and safety signals in children: A nationwide database study. Front Pharmacol  2020,11,964","journal-title":"Front Pharmacol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s40264-020-00911-w","volume":"43","author":"Caster O.","year":"2020","unstructured":"Caster O.; Aoki Y.; Gattepaille L.M.; Grundmark B.; Disproportionality analysis for pharmacovigilance signal detection in small databases or subsets: Recommendations for limiting false-positive associations. Drug Saf  2020,43(5),479-487","journal-title":"Drug Saf"},{"key":"ref=8","unstructured":"Pharmacovigilance Guidance material.  Available from: \n https:\/\/allaboutpharmacovigilance.org\/(Accessed on: 25th June 2022)."},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.1111\/bcp.14868","volume":"87","author":"B\u00f6hm R.","year":"2021","unstructured":"B\u00f6hm R.; Bulin C.; Waetzig V.; Cascorbi I.; Klein H.J.; Herdegen T.; Pharmacovigilance-based drug repurposing: The search for inverse signals via OpenVigil identifies putative drugs against viral respiratory infections. Br J Clin Pharmacol  2021,87(11),4421-4431","journal-title":"Br J Clin Pharmacol"},{"key":"ref=10","unstructured":"WHO Signal.   Available from:\n https:\/\/who-umc.org\/signal-work\/what-is-a-signal\/(Accessed on: 25th June 2022)."},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"e28671","DOI":"10.1002\/jmv.28671","volume":"95","author":"Sharma A.","year":"2023","unstructured":"Sharma A.; Roy S.; Sharma R.; Kumar A.; Association of antiviral drugs and their possible mechanisms with DRESS syndrome using data mining algorithms. J Med Virol  2023,95(3),e28671","journal-title":"J Med Virol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1080\/14740338.2023.2189698","volume":"22","author":"Jain D.","year":"2023","unstructured":"Jain D.; Sharma G.; Kumar A.; Adverse effects of proton pump inhibitors (PPIs) on the renal system using data mining algorithms (DMAs). Expert Opin Drug Saf  2023,22(8),741-752","journal-title":"Expert Opin Drug Saf"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2174\/1574886318666230228142856","volume":"19","author":"Javed F","year":"2024","unstructured":"Javed F; Kumar A; Identification of signal of clindamycin associated renal failure acute: A disproportionality analysis. Curr Drug Saf  2024,19(1),123-8","journal-title":"Curr Drug Saf"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/ane.13690","volume":"146","author":"Sharma A.","year":"2022","unstructured":"Sharma A.; Kumar A.; Identification of novel signal of clobazam-associated drug reaction with eosinophilia and systemic symptoms syndrome: A disproportionality analysis. Acta Neurol Scand  2022,146(5),623-627","journal-title":"Acta Neurol Scand"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s40278-017-28932-x","volume":"1647","year":"2017","unstructured":"Pomalidomide. Reactions Weekly  2017,1647(1),240","journal-title":"Reactions Weekly"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"766125","DOI":"10.3389\/fphar.2021.766125","volume":"12","author":"Zhou X.","year":"2021","unstructured":"Zhou X.; Ye X.; Guo X.; Safety of SGLT2 inhibitors: A pharmacovigilance study from 2013 to 2021 based on FAERS. Front Pharmacol  2021,12,766125","journal-title":"Front Pharmacol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"101","DOI":"10.4103\/0976-0105.160753","volume":"6","author":"Cheungpasitporn W.","year":"2015","unstructured":"Cheungpasitporn W.; Srivali N.; Thongprayoon C.; Ungprasert P.; Acute pancreatitis in the use of canagliflozin: A rare side-effect of the novel therapy for type 2 diabetes mellitus. J Basic Clin Pharm  2015,6(3),101-102","journal-title":"J Basic Clin Pharm"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1002\/pds.5313","volume":"30","author":"Frent I.","year":"2021","unstructured":"Frent I.; Bucsa C.; Leucuta D.; Farcas A.; Mogosan C.; An investigation on the association between sodium glucose co-transporter 2 inhibitors use and acute pancreatitis: A VigiBase study. Pharmacoepidemiol Drug Saf  2021,30(10),1428-1440","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.nefro.2021.07.015","volume":"43","author":"Barata R.","year":"2023","unstructured":"Barata R.; Acute interstitial nephritis due to dolutegravir: The first case reported. Nefrologia  2023,43(3),370-73","journal-title":"Nefrologia"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"2050313X2210794","DOI":"10.1177\/2050313X221079444","volume":"10","author":"Hirigo AT","year":"2022","unstructured":"Hirigo AT; Gutema S; Eifa A; Ketema W; Experience of dolutegravir-based antiretroviral treatment and risks of diabetes mellitus. SAGE Open Med Case Rep  2022,10,2050313X2210794","journal-title":"SAGE Open Med Case Rep"},{"key":"ref=21","first-page":"653","volume":"6","author":"Miguel R-G.","year":"2021","unstructured":"Miguel R-G.; Siddharth C.; Sorab G.; Nisha A.; Ibrutinib induced atrial brillation complicated with massive hemoptysis. Medical and Clinical Research  2021,6(8),653-655","journal-title":"Medical and Clinical Research"}],"container-title":["Current Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115748863276447231108092936","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/223666\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115748863276447231108092936","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T10:56:24Z","timestamp":1725274584000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/223666\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115748863276447231108092936","relation":{},"ISSN":["1574-8863"],"issn-type":[{"type":"print","value":"1574-8863"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-08-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-19","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}